Savara Inc (SVRA)
Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases in the United States. Its lead program is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor that is being developed in Phase 3 studies for autoimmune pulmonary alveolar proteinosis. Founded in 2007, Savara is headquartered in Langhorne, Pennsylvania. The company’s common stock trades on the NASDAQ under the ticker SVRA.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SVRA
|
—
|
—
|
—
|
$10.94
|
84.9% Upside
|
Unknown
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-11.4x
|
8.4x
|
—
|
1.392 B
|
1.308 B
|
2.1%
|
51.3%
|
13.0
|
—
|
82.6%
|
